Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 20, 2025
Aeroflow Health Donates to Women-Owned Businesses to Support Ongoing Hurricane Helene Relief Efforts
GlobeNewswire
·
March 20, 2025
ASHEVILLE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Today Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services, announced it has made a monetary donation to WE ARE— …
NativePath Native Hydrate Reviews: Breakthrough Zero-Sugar Hydration Solution Making Waves
GlobeNewswire
·
March 20, 2025
WOODHAVEN, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- What if the key to better hydration and muscle recovery wasn’t in sugary sports drinks but in a clean, science-backed formula? Native Hydrate, also known as NativePath Hydrate, is quickly gaining …
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
GlobeNewswire
·
March 20, 2025
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive …
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
GlobeNewswire
·
March 20, 2025
BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx’s system seeks to enhance …
Universe Pharmaceuticals INC Announces Share Consolidation
GlobeNewswire
·
March 20, 2025
Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share …
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
GlobeNewswire
·
March 20, 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its …
TOMI Environmental Solutions Selected by NASA for Biosecurity Operation
GlobeNewswire
·
March 20, 2025
FREDERICK, Md., March 20, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions developed through DARPA technology, today announced the deployment of its …
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology
GlobeNewswire
·
March 20, 2025
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving …
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
GlobeNewswire
·
March 20, 2025
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal …
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light
GlobeNewswire
·
March 20, 2025
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
GlobeNewswire
·
March 20, 2025
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, …
USDA Informs NAPIGEN, Inc. Its CMS Rice Is Not Subject to Regulation
GlobeNewswire
·
March 20, 2025
WILMINGTON, Del., March 20, 2025 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture has recently issued a Response to the Am I Regulated (AIR) Inquiry from NAPIGEN, Inc. notifying the company that its rice with gene-edited mitochondrial DNA is not …
CorVista Health to Present New Data on Non-Invasive Point of Care Test for Pulmonary Capillary Wedge Pressure Elevation Using Machine Learning at ACC.25
GlobeNewswire
·
March 20, 2025
BETHESDA, Md., March 20, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for pulmonary capillary wedge pressure (PCWP) elevation – a key indicator of heart failure …
PBGH Advisory Services Available Nationwide to Provide Fiduciary Support to Employers Sponsoring Health Benefits
GlobeNewswire
·
March 20, 2025
Oakland, California, March 20, 2025 (GLOBE NEWSWIRE) -- Purchaser Business Group on Health (PBGH), a nonprofit coalition representing 40 private employers and public entities across the U.S., today announced general availability of PBGH Advisory Services …
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
GlobeNewswire
·
March 20, 2025
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the …
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
·
March 20, 2025
Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million 2024 year-end cash and cash equivalents of $69. …
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire
·
March 20, 2025
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under …
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
GlobeNewswire
·
March 20, 2025
– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Secure …
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
GlobeNewswire
·
March 20, 2025
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it …
Nitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease
GlobeNewswire
·
March 20, 2025
- Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated Alpha-synuclein, a Hallmark of Parkinson’s Disease (PD) -Company Advancing Both NDC-0524, a Monoclonal Antibody with High …